Stocktoria
Profusa, Inc. PFSA
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-12-20
Profusa, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | $100,000 | — | — |
| R&D expense | $2.8M | $1.6M | — | — |
| Operating income | -$27.7M | -$4.5M | -$1.5M | -$1.3M |
| Income tax | — | $80,513 | $456,790 | $499,211 |
| Net income | -$35.8M | -$9.2M | $1.2M | $7.2M |
| EPS (diluted) | $-107.01 | $-357.14 | $0.12 | $0.30 |
| Operating cash flow | -$16.2M | -$2.1M | -$2.1M | -$581,189 |
| Free cash flow | -$16.3M | — | — | — |
| Cash & equivalents | $1.8M | $191,000 | $4,519 | $193,486 |
| Total assets | $3.8M | $3.1M | $10.9M | $194.7M |
| Total liabilities | $30.4M | $57.1M | $5.1M | $1.8M |
| Shareholders' equity | -$26.7M | -$119.2M | -$110.0M | -$619,476 |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net income growth | — | -894.4% | -83.8% | — |
| EPS growth | — | -297716.7% | -60.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.